Kornimate/medical-research-clean huggingface dataset:
pilot study on the feasibility of using smartphone data as a diagnostic marker for alzheimer's disease.

Conditions: Alzheimer Disease; Memory Disorders

Summary: this study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or alzheimer's disease.

alzheimer's disease (ad) is the leading cause of dementia in the world. the first cognitive function affected is memory and then other cognitive systems are affected leading to a progressive loss of autonomy of the patient. currently, the diagnosis of ad is made at too late a stage. patients with memory complaints or mild cognitive decline (mci) are particularly at risk of developing ad. however, there is no clinical or paraclinical evidence to predict precisely this risk of progression to ad. investigator's hypothesis is that there is an association between the evolution of smartphone use and the conversion of cognitive status to ad. the purpose of this pilot study is to identify existing differences between smartphone use data of patients with a memory complaint or of patients mci or with an ad. it is a study of 90 patients (30 patients with memory complaint, 30 with mci and 30 with ad) with a collection of smartphone usage data during three months.

Eligibility criteria:
inclusion criteria: * patient consulting in routine care in one of the cmrr * no sensory impairment that may compromise smartphone use exclusion criteria: * inability to perform mmse or mmse \< 20 ; * other neurodegenerative condition (parkinson's disease, lewy body disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis) * severe anxiety or depressive disorder hads score ≥ 17 * terminal phase of a severe disease * evidence of a lesion on mri that may be involved in cognitive impairment

Keywords: alzheimer disease smartphone memory disorders
ramipril 10 mg/day prevention

Conditions: Atherosclerosis

Summary: the objective is to investigate the safety of ramipril 10 mg/day used in prevention of cardiovascular events in high-risk patients, including the criteria of the hope study.


Eligibility criteria:
inclusion criteria: * history of coronary artery disease, * stroke * stable heart failure * peripheral vascular disease, or diabetes with at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette smoking, or documented microalbuminuria). exclusion criteria: * non stabilized or nyha grade iv heart failure patients * hemodynamically significant primary valvular or outflow tract obstruction (eg. mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve) * constrictive pericarditis. * complex congenital heart disease. * syncopal episodes presumed to be due to uncontrolled life-threatening arrhythmias (asymptomatic cardiac arrhythmias including ventricular tachycardia are not an exclusion criterion). * planned cardiac surgery or angioplasty within 3 months (patient may be reconsidered for the trial after the procedure). * cor pulmonale. * heart transplant recipient. * significant renal disease defined as: * renal artery stenosis; * creatine clearance \<0.6 ml/second or serum creatinine≥ 200 meq/l (≥2.26 mg/dl) * overt nephropathy: ≥1 plus proteinuria on dipstick or urinary albumin excretion \> 200 micrograms/minute (300 mg/24 hrs) * hyperkalemia; k\>5.5 meq/l. * patient is simultaneously taking another experimental drug. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
a trial of carboplatin and gemcitabine versus gemcitabine alone in patients with non-small-cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: to determine and compare the median survival produced by combined gemcitabine plus paraplatin versus gemcitabine as a single-agent in patients with nsclc and a ps equal to 2.


Eligibility criteria:
inclusion criteria: * histologic or cytologic new diagnosis of nsclc, stage iiib with a cytologically positive pleural or pericardial effusion or stage iv. * no prior chemotherapy, including adjuvant or neoadjuvant therapy, for the treatment of nsclc. * ecog performance status of 2 . * patients must be at least 3 weeks since major surgery. patients must be at least 1 week since surgery, such as mediastinoscopy, pleuroscopy, or thoracostomy. * patients must have measurable disease, defined as lesions that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than 10 mm with spiral ct scan. exclusion criteria: * any prior radiation therapy to the thoracic area. * active and ongoing systemic infection. * prior radiation to greater than 25% of the bone marrow. * ecog ps other than 2 * patients with a known hypersensitivity to gemcitabine and carboplatin.
harnessing the effect of an open-label placebo on fatigue in cancer survivors

Conditions: Fatigue in Cancer Survivors

Summary: this research study is evaluating the usefulness of a placebo (a tablet with no active ingredients) on fatigue in cancer survivors.

fatigue can be a problem for some people after cancer treatment. in clinical trials, placebos (tablets with no active ingredients) have been shown to improve symptoms of some medical conditions including fatigue. this study is being done to test the usefulness of taking placebos for improving cancer-related fatigue. in this study, the investigators are testing whether symptoms of fatigue will improve when people know they are taking a tablet with no active ingredients. this is a randomized study, which means the participant will be put into one of two groups. because no one knows which of the study options is best, the participant will be 'randomized' into one of the two study groups. randomization means that the participant will be put into a group by chance. it is like flipping a coin. neither the participant nor the research doctor will choose what group he or she will be in. the participant will have an equal chance of being placed in each of the groups.

Eligibility criteria:
inclusion criteria: * cancer survivor, with no evidence of active disease * ≥18 years of age * ≥6 months and \<10 years post active treatment * reports being bothered by fatigue in the past month and has a score of \<43 on facit-f. * able to read and write in english exclusion criteria: * being evaluated or likely to be evaluated for a medical cause of fatigue (e.g., anemia, hypothyroidism) during the study. (per provider report) * have indications of sleep apnea as assessed by epworth sleepiness scale score ≥10. * are receiving, or are likely to receive another intervention for the treatment of fatigue during the study period. (per provider report)

Keywords: fatigue in cancer survivors
effect of vitamind3 or 25(oh)d3 fortified dairy on vitmain d status and cvd risk markers

Conditions: Hypovitaminosis D; Cardiovascular Diseases

Summary: this study aims to compare the acute effect of consuming milk and butter fortified with either vitamin d3 or 25 (oh) d3 on serum/plasma vitamin d status in humans. in addition, the effect of vitamin d3 or 25 (oh) d3 in milk and butter on certain cvd risk markers and cognitive function will be examined.

there is mounting evidence to show that vitamin d deficiency may increase the risk of many common and serious diseases, including osteoporosis, cardiovascular disease, some cancers and type 1 diabetes (holick and chen, 2008). hypovitaminosis d is now prevalent in the uk general population. due to diet and lifestyle changes and the use of sun block products most people do not endogenously synthesise sufficient vitamin d from sunlight exposure (hyppönen and power, 2007). therefore, vitamin d intakes from dietary sources have become very important, however this is limited as there are only a few foods naturally rich in vitamin d. some countries (e.g. usa, canada) fortify milk with vitamin d which results in milk being the major contributor to vitamin d intake. vitamin d3 is the most common form used for the fortification of currently fortified foods. however, there is now some evidence that 25(oh)d3 can increase vitamin d status of humans more effectively than vitamin d3 (bischoff-ferrari et al, 2012; cashman et al, 2012). to our knowledge, very few human intervention studies have compared the efficacy of 25(oh)d3 versus vitamin d3 to increase vitamin d status, and there has been no acute human study to examine the effect of the both forms of vitamin d fortified dairy products on vitamin d status in humans.

Eligibility criteria:
inclusion criteria: * bmi: 20-35 kg/m2 * glucose \<7 mmol/l (not diagnosed with diabetes) * total cholesterol \<7 mmol/l * tag \<4 mmol/l * serum 25(oh)d3 ≤50 nmol/l * normal liver and kidney function * haemoglobin: adult male \>125 g/l exclusion criteria: * milk allergy/intolerance or lactose intolerance * cardiovascular, renal, gastrointestinal, respiratory, endocrine disease or cancer * use of nutritional supplements, particularly those containing vitamin d * outdoor workers and use of tanning beds * overseas holidays two months before or during study period

Keywords: vitamin d3 25(oh)d3 vitamin d status risk factors of cardiovascular diease
prevention of capsular contracture in postmastectomy patients undergoing implant-based reconstructions

Conditions: Capsular Contracture Associated With Implant

Summary: the study plans to evaluate capsular contracture at 1-year follow-up in postmastectomy patients receiving immediate implant-based reconstruction and capsulase® supplementation in the postoperative period. these data are compared with historical data of capsular contracture in patients not receiving any food supplementation postoperatively. aim of the study is to collect preliminary data to support capsulase® supplementation in the postoperative period to prevent capsular contracture.

capsular contracture is one of the most common complications of breast implant use, in both reconstructive and aesthetic setting. research on capsular contracture has focused on reducing bacterial contamination of implant surfaces through antibiotic and antiseptic solutions and, more recently, on the pharmacological control of the inflammation process around the implant. the foreign body reaction is responsible for capsular contracture. several experimental studies have demonstrated that it is possible to pharmacologically control the inflammation process around implants reducing the profibrotic substances included in the inflammation pathway. among diet supplements there are several substances that have been studied for their anti-inflammatory properties, in particular omega-3 fatty acids and boswellic acids. capsulase® is a diet supplement and consists of boswellia serrata phospholipid indena®, palmitoylethanolamide (pea), quercetin phytosome indena®, bromelain 2500 gelatin dissolving units/gram (gdu/g) and vitamin e acetate. its efficacy and safety in women with contracted breast implants have been evaluated both in the reconstructive and aesthetic setting. although preliminary results are satisfactory, however the series include a small sample of women. aim of this study is to collect preliminary data to support capsulase® supplementation in the postoperative period to prevent capsular contracture, comparing capsular contracture in postmastectomy patients receiving immediate implant-based reconstruction and capsulase® supplementation in the postoperative period with historical data of capsular contracture in patients not receiving any food supplementation postoperatively.

Eligibility criteria:
inclusion criteria: * immediate post mastectomy reconstruction with definitive silicone implant (microtextured prosthesis) (both therapeutic and risk reducing mastectomies) * informed consent * unilateral and bilateral mastectomies exclusion criteria: * hypersensitivity to capsulase® * pregnant women * impossibility of immediate reconstruction with definitive implants due to inadequacy of mastectomy flaps (inadequate in quantity and/or quality) * patients with previous breast implants * revisional surgery for capsular contracture * use of micro polyurethane foam-coated implants * mesh and matrix-assisted reconstructions * reconstruction of previous irradiated breasts

Keywords: capsular contracture mastectomy reconstruction definitive silicone implant
phase ii trial of neo-adjuvant temozolomide prior to combined temozolomide and concurrent accelerated hypofractionated external beam radiotherapy followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

Conditions: Glioblastoma Mutliforme

Summary: patients with gbm, who were deemed ineligible for any active protocols at our centre, received accelerated hypofractionation ebrt if 60gy/20fx using an imrt technique with conventional dose of concomitant and adjuvant tmx as per the stupp's tmz schedule. thirty five patients, 15 females and 20 males with a median age of 63 (range 31-78) were treated with a median kps of 90 (range 50-100). four patients had multicentric disease at presentation. eight patients had biopsy only while the rest had a near total resection (n=14) and partial resection (n=13) with a median follow-up of 12.1 months, the median survival was 14.4 months.

in this proposal, the total cumulative dose of tmz is unchanged as compared to the doses used in the stupp protocol. in this proposal, the dose of tmz is the same, with the sole difference that tmz will be given in a neo-adjuvant setting for two weeks and then continued at the same dose concurrently with the accelerated hypofractionated ebrt delivering 60gy in 4 weeks. the adjuvant component of tmz remains unchanged from current standard practice.

Eligibility criteria:
inclusion criteria: * age: 18 years or older * histological confirmation of supratentorial gbm * kps \> 60 * neurological function 0 or 1 * adequate bone marrow as defined below: * absolute neutrophil count (anc) \> 1500 cells/mm3 * platelets \> 100,000 cells/mm3 * hemoglobin \> 10g/dl * adequate renal function as defined below: * bun \< 25mg/dl within 14 days prior to study registration * creatinine of 63 to 103 umol/l within 14 days prior to study registration * adequate hepatic function as defined below: * bilirubin of 3 to 21 umol/l within 14 days prior to study registration * alt \& ast \< 3xnormal range within 14 days prior to study registration * neoadjuvant tmz to start within 3 weeks of surgery/biopsy if no resection was deemed feasible * a diagnostic contrast-enhanced mri or ct scan of the brain must be performed preoperatively and postoperatively. * history, physical and neurological examination within 14 days prior to study registration. * for females of child-bearing potential, negative pregnancy test within 72 hours prior to starting tmz. * able to sign an informed study-specific consent exclusion criteria: * margin of contrast-enhanced residual mass closer than 15mm from the optic chiasm or optic nerves. * prior invasive malignancy, unless disease-free for \>3years * recurrent or multifocal gbm * severe co-morbidities such as * unstable angina * transmural myocardial infarction within 6 months * copd at the time of registration * hepatic insufficiency * bacterial or fungal infection requiring iv antibiotics at the time of registration * acquired immune deficiency syndrome (aids) * major medical illnesses or psychiatric impairments * pregnant women or lactating women
new cvd risk factors for lowered cognitive functioning

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Neurologic Manifestations

Summary: to explore the associations between cognitive functioning and three major cardiovascular disease risk factors: high blood pressure; high total plasma homocysteine (thcy); and apoe e4 genotype.

background: arterial hypertension and high blood pressure (hbp) are major risk factors for cardiovascular disease (cvd) and stroke; they are also risk factors for lowered cognitive functioning. except for diabetes, there have been comparatively few studies of other common risk factors, particularly with regard to interrelationships among risk factors which may adversely affect cognitive ability. design narrative: the study examines associations between cognitive functioning and three cardiovascular risk factors: 1) high blood pressure; 2) high total plasma homocysteine (thcy), and 3) apoe e4 genotype. these associations are examined cross-sectionally as well as longitudinally, using data collected at a follow-up visit of members of a cohort that has been followed for the past 18-19 years. longitudinal data are used to examine both current and change in cognitive functioning. some analyses are prospective (e.g., high blood pressure and change in cognitive functioning), while others are cross-sectional (e.g., apoe e4 and current cognitive functioning) or retrospective (e.g., thcy and change in cognitive functioning). structural equation models are used to examine cross-sectional data in elucidating a general theoretical model. two-stage growth curve analyses and survival analyses are appropriate methods for analyzing the longitudinal data. the study includes a very comprehensive set of measures that have already been collected or will be collected during the follow-up visit. all potential confounders of the association between the three target predictor variables and the various domains of cognitive functioning appear to have been included in this design.

Eligibility criteria:
no eligibility criteria
phase 2 study of urc102 to assess the efficacy and safety in gout patients

Conditions: Gout; Hyperuricemia

Summary: the purpose of this study is to assess safety, pk/pd and urate lowering effect of urc102 in gout patients with hyperuricemia


Eligibility criteria:
inclusion criteria: * diagnosed with gout exclusion criteria: * participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)
mri findings of encephalopathy associated with carbon dioxide (co2) intoxication

Conditions: CO2 Intoxication

Summary: carbon dioxide intoxication is a rare condition and only few case reports are found in the literature. there were six patients who suffered from carbon dioxide intoxication in our hospital about two years ago. two of them are more severe with conscious change and brain mri studies of the two patients were performed. reviewing the literature, no any report has mentioned about the encephalopathy associated with carbon dioxide intoxication. we want to review the brain lesions on the diffusion weighted images and the laboratory data of the patients for further diagnostic help.


Eligibility criteria:
inclusion criteria: * co2 intoxication exclusion criteria: * none co2 intoxication

Keywords: carbon dioxide intoxication diffusion weighted images(dwi)
optimized c-arm cone beam ct for the endovascular treatment (evt) of acute stroke

Conditions: Stroke, Acute

Summary: when it comes to acute stroke, everyone deserves the best care. today, more patients can benefit from endovascular treatment (evt) in a comprehensive stroke center. with the significant advances in c-arm cone beam ct (cbct) imagings directly in the neuro angio-suite (nas), the investigators are now able to identify, plan and treat stroke patients in the nas, without the need for a separate ct scan. this provides valuable, time-saving support for critical patients in acute need of evt. the main objective is to assess the diagnostic confidence of this optimized c-arm cone beam ct, named in french aso, in the nas for the detection of brain abnormalities and hemorrhagic complications for critical patients with acute stroke. the secondary objectives are to study the variability of the diagnostic accuracy concerning the staging of the stroke, the analysis of the brain vessel, the relevance of artefact reduction post treatment and the amount of dose for this aso.

design: aso-avc is a french academic pilot study by exploring the diagnostic confidence of optimized c-arm cone beam ct (aso) realized directly in the neuro angio-suite (nas). to compare the effectiveness and safety of aso diagnostic, the variability of the diagnostic accuracy concerning the staging of the stroke, the analysis of the brain vessel, the relevance of artefact reduction post treatment and the amount of delivered dose, the investigator proposed to assess clinical usefulness of aso in the diagnostic process of stroke. intervention: no modification of patient care will be required by this protocol. all patients participating in the study will undergo standard diagnostic, procedural and control imagings, which consist of : diagnostic imaging studies (mri or ct scan), usual c-arm cone beam ct in the nas during evt to insure no procedural complication and control imaging studies (mri or ct scan) at 24 hours ; decisions concerning further diagnostics will be made by the physician in charge. apart from theses standard imagings, patients will undergo the aso. the aso imagings will be anonymized and recorded in a centralized database called pacs (picture archiving and communication system), in order to a centralized radiological reading by the imaging core lab. they will be reviewed by radiologist readers to rate diagnostic image quality through a questionnaire, and in a second time the data will be included in a comparative evaluation with the diagnostic and control imagings.

Eligibility criteria:
inclusion criteria: aged ≥ 18 years diagnosed with an acute stroke and needed for a evt affiliation to compulsory french social security scheme (beneficiary or right-holder) consent from the patient if their level of consciousness is sufficient or from their relatives. if none is possible at the inclusion, consent will be obtained as soon as possible exclusion criteria: being under tutelage or legal guardianship ; ongoing pregnancy, breastfeeding

Keywords: cerebrovascular disorders brain diseases central nervous system diseases nervous system diseases vascular diseases